A growing list of neuropeptides — including oxytocin, vasopressin, neuropeptide Y, neuropeptide S, and Substance P — show promise as therapeutic targets, diagnostic markers, and treatment approaches for anxiety and depression.
Current treatments fail many patientsDespite numerous antidepressants and anxiolytics available, many patients with anxiety and depression do not achieve remission. Neuropeptides represent a fundamentally different class of therapeutic targets that could fill this treatment gap.
What the researchers found
The review identifies multiple neuropeptide systems implicated in anxiety and depression: oxytocin (anxiolytic and antidepressant properties), vasopressin (stress response regulation), neuropeptide Y (stress resilience and anti-anxiety effects), neuropeptide S (anxiolytic potential), and Substance P (pro-anxiety and pro-depressive when elevated, with NK1 antagonists showing antidepressant effects).
Many neuropeptides act as neuromodulators co-released with classical neurotransmitters, enabling communication between brain and body. The review notes that novel neuropeptides are increasingly being identified as having implications for mood disorder research, expanding the pool of potential therapeutic targets beyond traditional neurotransmitter-based approaches.
Why it matters
Depression and anxiety are among the most common mental health conditions worldwide, yet current medications are inadequate for many patients. Neuropeptides represent a fundamentally different class of targets from traditional neurotransmitter-based drugs. Understanding their roles could lead to entirely new classes of psychiatric medications with different mechanisms of action and potentially better outcomes for treatment-resistant patients.
How the study worked
Comprehensive narrative review of published research on neuropeptides in anxiety and depression, covering both human and animal model studies. The authors examined neuropeptide pathways, roles in stress adaptation, and the etiology of mood disorders, with a focus on the latest research findings and emerging neuropeptide targets.
What this study cannot tell us
This is a review article that synthesizes existing literature without presenting new experimental data. The translation from animal neuropeptide research to human psychiatric treatments has been historically challenging. Many neuropeptide-based drug candidates have failed in clinical trials despite promising preclinical data. The blood-brain barrier presents a delivery challenge for peptide-based therapies targeting brain circuits.
How to read the evidence
This is a narrative review covering a broad range of neuropeptide research from both human and animal studies. While it provides a useful overview of the field, the evidence strength for individual neuropeptides varies widely, from robust clinical trial data to preliminary animal studies.
When this study was published
Published in 2022, this review captures the current state of neuropeptide research in psychiatry, including both established and emerging targets.
The bigger picture
Psychiatric drug development has been largely stagnant, with most medications still targeting the same monoamine neurotransmitter systems identified decades ago. Neuropeptides offer a paradigm shift — they are more specific, act through different pathways, and could enable more targeted treatments. The field of neuropeptide-based psychiatry is gaining momentum, with several NK1 receptor antagonists and oxytocin formulations having entered clinical trials for mood disorders.
Questions still open
- Which neuropeptide targets are most likely to yield successful psychiatric medications in clinical trials?
- Can neuropeptide levels serve as reliable biomarkers for diagnosing or subtyping anxiety and depression?
- How can the blood-brain barrier delivery challenge be overcome for peptide-based psychiatric treatments?
Common questions
What are neuropeptides and how do they relate to mental health?
Could neuropeptide-based drugs work where current antidepressants fail?
Read the original research
Anxiety and Depression: What Do We Know of Neuropeptides?
Behavioral sciences (Basel, Switzerland), 12(8)
Citation
Kupcova, Ida; Danisovic, Lubos; Grgac, Ivan; Harsanyi, Stefan. (2022). Anxiety and Depression: What Do We Know of Neuropeptides?. Behavioral sciences (Basel, Switzerland), 12(8). https://doi.org/10.3390/bs12080262